Literature DB >> 15725097

Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice.

Roger G Owen, Andy C Rawstron.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15725097     DOI： 10.1111/j.1365-2141.2005.05376.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  High-content flow cytometry and temporal data analysis for defining a cellular signature of graft-versus-host disease.

Authors:  Ryan Remy Brinkman; Maura Gasparetto; Shang-Jung Jessica Lee; Albert J Ribickas; Janelle Perkins; William Janssen; Renee Smiley; Clay Smith
Journal:  Biol Blood Marrow Transplant       Date:  2007-04-06       Impact factor: 5.742

2.  Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria.

Authors:  Kentaro Narita; Daisuke Miura; Takafumi Tsushima; Toshiki Terao; Ayumi Kuzume; Rikako Tabata; Masami Takeuchi; Kosei Matsue
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

3.  Detection of minimal residual disease by flow cytometry for patients with multiple myeloma submitted to autologous hematopoietic stem cell transplantation.

Authors:  Suzane Dal Bó; Annelise Pezzi; Bruna Amorin; Vanessa Valim; Rosane Isabel Bittencourt; Lucia Silla
Journal:  ISRN Hematol       Date:  2013-06-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.